RRM1、ERCC1蛋白表达与晚期NSCLC患者GP方案化疗疗效及预后相关性分析

山东大学学报(医学版) ›› 2011, Vol. 49 ›› Issue (6): 89-93.

RRM1、ERCC1蛋白表达与晚期NSCLC患者GP方案化疗疗效及预后相关性分析

杨宁，韩俊庆，盛巍

山东大学附属省立医院肿瘤中心，济南 250021

收稿日期:2010-09-27 出版日期:2011-06-10 发布日期:2011-06-10
通讯作者: 韩俊庆(1960- )，男，教授，主要从事放射肿瘤学的研究。 E-mail：hanjunqing1960@126.com
作者简介:杨宁(1984- )，男，硕士研究生，主要从事肺癌的研究。E-mail：yangning-sdu@yahoo.cn

Relationship of expressions of RRM1 and ERCC1 proteins with response and prognosis in advanced NSCLC patients receiving cisplatin combined with gemcitabine chemotherapy

YANG Ning, HAN Jun-qing, SHENG Wei

Center for Oncology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China

Received:2010-09-27 Online:2011-06-10 Published:2011-06-10

摘要/Abstract

摘要：

目的探讨RRM1、ERCC1蛋白表达与晚期(IIIB~IV)非小细胞肺癌(NSCLC)吉西他滨联合顺铂(GP)方案化疗疗效及预后的关系。方法回顾性分析47例曾接受GP方案化疗的晚期NSCLC患者的临床病理资料,采用免疫组织化学法检测病理标本中RRM1、ERCC1蛋白表达，对化疗疗效及生存时间进行分析。结果 RRM1、ERCC1蛋白阳性率分别为46.81%(22/47)、42.55%(20/47),其表达与性别、年龄、PS评分、组织学类型、分期、吸烟均无相关性，化疗有效率为36.17%(17/47), RRM1、ERCC1蛋白阳性及阴性患者化疗有效率分别为18.18%(4/22)和52.00%(13/25)，20.00%(4/20)和48.15%(13/27),差异有统计学意义(P=0.016、0.047)。RRM1、ERCC1蛋白低表达者中位生存期皆为14.1个月，RRM1、ERCC1蛋白高表达者中位生存期分别为6.8、7.1个月(P=0.008、0.017)；RRM1、ERCC1蛋白均阴性表达者的预后明显好于1个或2个阳性表达者, 中位生存期分别为14.8、7.6个月(P=0.012)。COX回归分析显示，分期是晚期NSCLC的独立预后影响因素。结论 RRM1、ERCC1表达水平与NSCLC患者GP方案的化疗近期疗效及预后为负相关关系，RRM1、ERCC1低表达的晚期NSCLC患者更能从GP方案中获益。

关键词: 肺肿瘤；免疫组织化学；基因；吉西他滨/顺铂

Abstract:

Objective To explore the relationship of expressions of ribonucleotide reductase M1 RRM1 and excision repair cross complementation 1(ERCC1) proteins with response and prognosis of patients with advanced(IIIB-IV) non-small cell lung cancer (NSCLC) receiving cisplatin combined with gemcitabine (GP) chemotherapy. Methods Clinical pathological data from 47 advanced NSCLC patients who received GP chemotherapy were retrospectively analyzed, and their tumor samples were collected. Expressions of RRM1 and ERCC1 proteins in tumor samples were detected by the immunohistochemical method. The therapeutic effect and survival time were analyzed. Results RRM1 and ERCC1 positive rates were 46.81%(22/47)and 42.55%(20/47)， respectively. There was no correlation of RRM1 and ERCC1 expressions with gender，age, PS scores, pathological type，TNM stage and smoking. The overall response rate was 36.17%(17/47). Response rates were 18.18%(4/22) and 52.00%(13/25) respectively in patients with high and low RRM1 expressions(P=0.016), while they were 20.00%(4/20) and 48.15%(13/27)in patients with high and low ERCC1 expressions， respectively(P=0.047). Low expression of RRM1 or ERCC1 protein was correlated with longer median overall survival (14.1 months， 14.1 months), while the median overall survival of high expression ofRRM1 or ERCC1 protein was 6.8months and 7.1months, respectively(P=0.008，0.017). Patients with low expressions of both RRM1 and ERCC1 proteins had longer median overall survival(14.8 months) than those with high expressions of RRM1 and/or ERCC1(7.6months)(P=0.012). Cox regression analysis revealed that the TNM stage was an independent prognostic factor. Conclusions Expressions of RRM1 and ERCC1 proteins have a negative correction with the response to GP chemotherapy and prognosis. Advanced NSCLC patients with low expression of RRM1 or ERCC1 may get more benefits from GP chemotherapy.

Key words: Lung neoplasms； Immunohistochemistry； Genes； Cisplatin/gemcitabine

中图分类号:

R734.2

杨宁，韩俊庆，盛巍. RRM1、ERCC1蛋白表达与晚期NSCLC患者GP方案化疗疗效及预后相关性分析[J]. 山东大学学报(医学版), 2011, 49(6): 89-93.

YANG Ning, HAN Jun-qing, SHENG Wei. Relationship of expressions of RRM1 and ERCC1 proteins with response and prognosis in advanced NSCLC patients receiving cisplatin combined with gemcitabine chemotherapy[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 89-93.

参考文献

相关文章 15

[1]	徐晓娅，毕玉莉，姜曼，许继映，张鹏飞，韩明勇. 血管内皮生长因子促进肺转移相关受体通路的研究[J]. 山东大学学报(医学版), 2013, 51(11): 25-29.
[2]	张鹏飞，隋萍，张颖，戴建建，林琦，韩明勇. 妊娠合并肝内胆管细胞癌多发转移1例[J]. 山东大学学报(医学版), 2013, 51(11): 108-110.
[3]	田甜甜1，李际盛1，王亚伟1，马道新2，王秀问1. 染料木黄酮在小细胞肺癌H446细胞中通过抑制FoxM1通路发挥抗肿瘤作用[J]. 山东大学学报(医学版), 2013, 51(06): 44-48.
[4]	刘冰1，于壮1，侯宪鹏1，姚如永2. EGFR和HER-3在人肺腺癌细胞及培美曲塞二钠耐药细胞中的表达差异[J]. 山东大学学报(医学版), 2013, 51(5): 20-23.
[5]	阿力木江·赛提瓦尔地，张涛，帕提古丽·阿尔西丁，刘莉. 重组人血管内皮抑素联合吉西他滨及顺铂治疗晚期非小细胞肺癌的临床分析[J]. 山东大学学报(医学版), 2013, 51(3): 95-98.
[6]	董雪丽，牟晓燕，刘庆亮，孙杰. 塞来昔布联合厄罗替尼对人肺癌裸鼠移植瘤生长及血管生成的影响[J]. 山东大学学报(医学版), 2013, 51(2): 49-52.
[7]	韩觉明,林琦,戴建建,张颖,韩明勇. 全内脏转位合并右肺癌1例[J]. 山东大学学报(医学版), 2012, 50(10): 130-131.
[8]	刘庆亮1，牟晓燕1，王静2，迟翔宇2，张敏3，马卫霞3. RNA干扰及厄洛替尼阻断EGFR信号途径对A549细胞抗增殖的影响[J]. 山东大学学报(医学版), 2012, 50(9): 11-.
[9]	范恒建，张玉可，肖伟，张一，李海军，王得翔 . 肺腺癌患者外周血Treg和Th17细胞的变化及其对预后的影响[J]. 山东大学学报(医学版), 2012, 50(9): 73-78.
[10]	王吉霞，李贵新，黄琰，王丽娟. 非小细胞肺癌组织中E1AF、MMP-7、uPA的表达及其临床意义[J]. 山东大学学报(医学版), 2012, 50(7): 109-.
[11]	徐统震，孙雪飞，任冬梅，杨国涛. 木犀草素抑制肺癌细胞A549的增殖及其联合化疗作用[J]. 山东大学学报(医学版), 2012, 50(7): 50-54.
[12]	刘海荣1，于金明2，李岩1，梁婧1，刘晓琳1. ER、PR、C-erB-2与肺腺癌骨转移的相关性研究[J]. 山东大学学报(医学版), 2012, 50(4): 91-.
[13]	马育华1，2, 郑燕3，郏雁飞3，汪运山3. EGFR与DEC1蛋白共表达促进肺腺癌肿瘤细胞淋巴结转移[J]. 山东大学学报(医学版), 2012, 50(3): 24-28.
[14]	孙雪飞，裴艳涛，尹秋伟，杨国涛，王德江. 藤梨根提取物对肺癌A549细胞裸鼠移植瘤的抑制作用[J]. 山东大学学报(医学版), 2012, 50(2): 38-42.
[15]	李鹏,刘奇,韩明勇. PET-CT、血清CEA及CYFRA21-1预测靶向药物对非小细胞肺癌疗效的研究[J]. 山东大学学报(医学版), 2012, 50(1): 129-132.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed